{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:53:48Z","timestamp":1758970428582},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T00:00:00Z","timestamp":1336608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10198-012-0395-6","type":"journal-article","created":{"date-parts":[[2012,5,9]],"date-time":"2012-05-09T16:43:58Z","timestamp":1336581838000},"page":"507-514","source":"Crossref","is-referenced-by-count":23,"title":["Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales"],"prefix":"10.1007","volume":"14","author":[{"given":"Ruth E.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujith","family":"Dhanasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Schey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,10]]},"reference":[{"key":"395_CR1","unstructured":"Cancer Research UK: Multiple myeloma\u2014UK incidence statistics. http:\/\/info.cancerresearchuk.org\/cancerstats\/types\/multiplemyeloma\/incidence\/index.htm (2010). Accessed 19 July 2011"},{"key":"395_CR2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2165\/11206420-000000000-00000","volume":"71","author":"LJ Scott","year":"2011","unstructured":"Scott, L.J., Lyseng-Williamson, K.A.: Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 71, 625\u2013649 (2011)","journal-title":"Drugs"},{"key":"395_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1586\/erp.10.19","volume":"10","author":"S Schey","year":"2010","unstructured":"Schey, S., Higginson, I.: Cost-effectiveness of lenalidomide in multiple myeloma. Expert Rev. Pharmacoecon. Outcomes Res. 10, 229\u2013238 (2010)","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"395_CR4","unstructured":"Drayson, M.T., Augustson, B.M., Begum, G., et al.: Survival from relapse and the influence of therapy (Abstract PO-665). Haematologica 92, 173 (2007)"},{"key":"395_CR5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., et al.: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516\u20132520 (2008)","journal-title":"Blood"},{"key":"395_CR6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","volume":"82","author":"EA Stadtmauer","year":"2009","unstructured":"Stadtmauer, E.A., Weber, D.M., Niesvizky, R., et al.: Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur. J. Haematol. 82, 426\u2013432 (2009)","journal-title":"Eur. J. Haematol."},{"key":"395_CR7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/leu.2011.3","volume":"25","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos, M.A., Palumbo, A., Attal, M., et al.: Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 25, 749\u2013760 (2011)","journal-title":"Leukemia"},{"key":"395_CR8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00019053-200523040-00003","volume":"23","author":"JJ Caro","year":"2005","unstructured":"Caro, J.J.: Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 23, 323\u2013332 (2005)","journal-title":"Pharmacoeconomics"},{"key":"395_CR9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos, M., Spencer, A., Attal, M., et al.: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123\u20132132 (2007)","journal-title":"N. Engl. J. Med."},{"key":"395_CR10","doi-asserted-by":"crossref","unstructured":"Weber, D., Knight, R., Chen, C. et al.: Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma. Blood 110, 412 (2007)","DOI":"10.1182\/blood.V110.11.412.412"},{"key":"395_CR11","unstructured":"National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. http:\/\/www.nice.org.uk\/media\/B52\/A7\/TAMethodsGuideUpdatedJune2008.pdf (June 2008). Accessed 19 July 2011"},{"key":"395_CR12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie, B.G., Harousseau, J.L., Miguel, J.S., et al.: International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006)","journal-title":"Leukemia"},{"key":"395_CR13","doi-asserted-by":"crossref","unstructured":"Ishak, K.J., Caro, J.J., Drayson, M.T., et al.: Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value Health 14, 672\u2013678 (2011)","DOI":"10.1016\/j.jval.2011.02.1182"},{"key":"395_CR14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ejca.2004.01.019","volume":"40","author":"M Agthoven van","year":"2004","unstructured":"van Agthoven, M., Segeren, C.M., Buijt, I., et al.: A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II\/III multiple myeloma; a prospective randomised phase III study. Eur. J. Cancer 40, 1159\u20131169 (2004)","journal-title":"Eur. J. Cancer"},{"key":"395_CR15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00019053-200725030-00005","volume":"25","author":"DF Ossa","year":"2007","unstructured":"Ossa, D.F., Briggs, A., McIntosh, E., Cowell, W., Littlewood, T., Sculpher, M.: Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics 25, 223\u2013237 (2007)","journal-title":"Pharmacoeconomics"},{"key":"395_CR16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd, A., Nafees, B., Narewska, J., Dewilde, S., Watkins, J.: Health state utilities for metastatic breast cancer. Br. J. Cancer 95, 683\u2013690 (2006)","journal-title":"Br. J. Cancer"},{"key":"395_CR17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1525-1497.1999.00320.x","volume":"14","author":"S Cykert","year":"1999","unstructured":"Cykert, S., Joines, J.D., Kissling, G., Hansen, C.J.: Racial differences in patients\u2019 perceptions of debilitated health states. J. Gen. Intern. Med. 14, 217\u2013222 (1999)","journal-title":"J. Gen. Intern. Med."},{"key":"395_CR18","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.2337\/diacare.25.12.2238","volume":"25","author":"JT Coffey","year":"2002","unstructured":"Coffey, J.T., Brandle, M., Zhou, H., et al.: Valuing health-related quality of life in diabetes. Diabetes Care 25, 2238\u20132243 (2002)","journal-title":"Diabetes Care"},{"key":"395_CR19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1177\/009286159903300421","volume":"33","author":"SD Mathias","year":"1999","unstructured":"Mathias, S.D., Putterman, C.G., Prebil, L.A., et al.: A health-related quality of life measure in patients with deep vein thrombosis: a validation study. Drug Inf. J. 33, 1173\u20131187 (1999)","journal-title":"Drug Inf. J."},{"key":"395_CR20","unstructured":"Department of Health: The 2009 pharmaceutical price regulation scheme. http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_091825 (December 11, 2008). Accessed 19 July 2011"},{"key":"395_CR21","unstructured":"Department of Health: NHS reference costs 2008\u20132009. http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_111591 (2010). Accessed 19 July 2011"},{"key":"395_CR22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson, P.G., Weller, E., Lonial, S., et al.: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679\u2013686 (2010)","journal-title":"Blood"},{"key":"395_CR23","unstructured":"Richards, M.: Improving access to medicines for NHS patients: a report for the Secretary of State for Health by Professor Mike Richards. http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_089927 (November 4, 2008). Accessed 19 July 2011"},{"key":"395_CR24","unstructured":"Steinbach, R.: Inequalities in the distribution of health and health care and its access, including inequalities relating to social class, gender, culture and ethnicity, and their causes. Equality, equity and policy: inequalities in the distribution of health and health care and its access. http:\/\/www.healthknowledge.org.uk\/public-health-textbook\/medical-sociology-policy-economics\/4c-equality-equity-policy\/inequalities-distribution (2009). Accessed 19 July 2011"},{"key":"395_CR25","unstructured":"Department of Health: Improving outcomes: a strategy for cancer. http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_123394.pdf (January 2011). Accessed 29 Feb 2012"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-012-0395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-012-0395-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-012-0395-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T10:34:56Z","timestamp":1594118096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-012-0395-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,10]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1007\/s10198-012-0395-6","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,10]]}}}